GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guangzhou LBP Medicine Science & Technology Co Ltd (SHSE:688393) » Definitions » Cash-to-Debt

Guangzhou LBP Medicine Science & Technology Co (SHSE:688393) Cash-to-Debt : 8.61 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Guangzhou LBP Medicine Science & Technology Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Guangzhou LBP Medicine Science & Technology Co's cash to debt ratio for the quarter that ended in Sep. 2024 was 8.61.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Guangzhou LBP Medicine Science & Technology Co could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Guangzhou LBP Medicine Science & Technology Co's Cash-to-Debt or its related term are showing as below:

SHSE:688393' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.24   Med: 132.26   Max: No Debt
Current: 8.61

During the past 11 years, Guangzhou LBP Medicine Science & Technology Co's highest Cash to Debt Ratio was No Debt. The lowest was 4.24. And the median was 132.26.

SHSE:688393's Cash-to-Debt is ranked better than
72.75% of 855 companies
in the Medical Devices & Instruments industry
Industry Median: 1.78 vs SHSE:688393: 8.61

Guangzhou LBP Medicine Science & Technology Co Cash-to-Debt Historical Data

The historical data trend for Guangzhou LBP Medicine Science & Technology Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Guangzhou LBP Medicine Science & Technology Co Cash-to-Debt Chart

Guangzhou LBP Medicine Science & Technology Co Annual Data
Trend Dec12 Dec13 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt 477.01 51.42 10.74 4.24

Guangzhou LBP Medicine Science & Technology Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.94 4.24 11.45 8.11 8.61

Competitive Comparison of Guangzhou LBP Medicine Science & Technology Co's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Guangzhou LBP Medicine Science & Technology Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangzhou LBP Medicine Science & Technology Co's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guangzhou LBP Medicine Science & Technology Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Guangzhou LBP Medicine Science & Technology Co's Cash-to-Debt falls into.



Guangzhou LBP Medicine Science & Technology Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Guangzhou LBP Medicine Science & Technology Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Guangzhou LBP Medicine Science & Technology Co's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guangzhou LBP Medicine Science & Technology Co  (SHSE:688393) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Guangzhou LBP Medicine Science & Technology Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Guangzhou LBP Medicine Science & Technology Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Guangzhou LBP Medicine Science & Technology Co Business Description

Traded in Other Exchanges
N/A
Address
Building 7, No. 11, Nanxiang 3rd Road, Guangzhou High-tech Industrial Development Zone, Guangdong Province, Guangzhou, CHN, 510663
Guangzhou LBP Medicine Science & Technology Co Ltd is engaged in production and sales of in vitro diagnostic reagents and instruments. The company's products include Fluorescence in situ hybridization (FISH) series; Immunohistochemistry (IHC) series; Liquid - based cytology (LBP) series; PCR series; and medical laboratory.
Executives
Zhu Jun Xuan Core technical personnel

Guangzhou LBP Medicine Science & Technology Co Headlines

No Headlines